Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:756-761

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wessely, R.
Right arrow Articles by Kandolf, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wessely, R.
Right arrow Articles by Kandolf, R.
Related Collections
Right arrow Genetically altered mice
Right arrow Growth factors/cytokines
Right arrow Heart failure - basic studies
Right arrow Myocardial cardiomyopathy disease

(Circulation. 2001;103:756.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling

Implications for Mortality and Early Viral Replication

Rainer Wessely, MD; Karin Klingel, MD; Kirk U. Knowlton, MD; Reinhard Kandolf, MD

From Deutsches Herzzentrum and 1 Medizinische Klinik (R.W.), Technische Universität, Munich, Germany; the Department of Molecular Pathology (K.K., R.K.), University Hospital Tübingen, Tübingen, Germany; and the Department of Medicine (K.U.K.), University of California, San Diego.

Correspondence to Kirk U. Knowlton, MD, University of California at San Diego, Department of Medicine, 9500 Gilman Dr, La Jolla, CA 92093. E-mail kknowlton{at}ucsd.edu

Background—Interferons (IFNs) play an important role in antiviral defense and have therapeutic potential in coxsackievirus heart disease. However, little is known about the relative contributions of type I and type II IFN signaling in coxsackievirus B3 (CVB3) infection or their role in the cardioselective nature of CVB3 infection.

Methods and Results—Wild-type mice and mice deficient for either the type I or the type II IFN receptor (IFNR) were infected with CVB3. Infection of the type I IFNR–deficient mice with >103 plaque-forming units (pfu) of CVB3 resulted in 100% mortality within 2 to 4 days after infection. Death was rare in wild-type and type II IFNR–deficient mice after inoculation with as much as 108 pfu of CVB3. Surprisingly, the early mortality in the type I IFNR–deficient mice was not accompanied by higher virus titers in the heart. Unexpectedly, a dramatic increase of viral RNA in the liver was found to correlate with early mortality in type I IFNR–deficient mice.

Conclusions—Type I but not type II IFN signaling is essential for the prevention of early death due to CVB3 infection. Interestingly, neither type I or type II IFN signaling has a dramatic effect on early viral replication in the heart. However, lethal viral replication in the liver is controlled by type I IFNs. These results demonstrate that the IFN system is capable of modulating both viral pathogenicity and tissue tropism.


Key Words: cardiomyopathy • myocarditis • immune system • infection




This article has been cited by other articles:


Home page
J. Virol.Home page
S. Ohka, H. Igarashi, N. Nagata, M. Sakai, S. Koike, T. Nochi, H. Kiyono, and A. Nomoto
Establishment of a Poliovirus Oral Infection System in Human Poliovirus Receptor-Expressing Transgenic Mice That Are Deficient in Alpha/Beta Interferon Receptor
J. Virol., August 1, 2007; 81(15): 7902 - 7912.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-X. Wang, V. da Cunha, J. Vincelette, K. White, S. Velichko, Y. Xu, C. Gross, R. M. Fitch, M. Halks-Miller, B. R. Larsen, et al.
Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H69 - H76.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Yajima, H. Yasukawa, E.-S. Jeon, D. Xiong, A. Dorner, M. Iwatate, M. Nara, H. Zhou, D. Summers-Torres, M. Hoshijima, et al.
Innate Defense Mechanism Against Virus Infection Within the Cardiac Myocyte Requiring gp130-STAT3 Signaling
Circulation, November 28, 2006; 114(22): 2364 - 2373.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Wessely
Interference by interferons: Janus faces in vascular proliferative diseases
Cardiovasc Res, June 1, 2005; 66(3): 433 - 443.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Merl, C. Michaelis, B. Jaschke, M. Vorpahl, S. Seidl, and R. Wessely
Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice
Circulation, April 5, 2005; 111(13): 1583 - 1592.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Grun, B. Markova, F.-D. Bohmer, A. Berndt, H. Kosmehl, and C. Leipner
Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis
Eur. Heart J., April 1, 2005; 26(7): 728 - 739.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Flodstrom-Tullberg, M. Hultcrantz, A. Stotland, A. Maday, D. Tsai, C. Fine, B. Williams, R. Silverman, and N. Sarvetnick
RNase L and Double-Stranded RNA-Dependent Protein Kinase Exert Complementary Roles in Islet Cell Defense during Coxsackievirus Infection
J. Immunol., February 1, 2005; 174(3): 1171 - 1177.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Deonarain, D. Cerullo, K. Fuse, P. P. Liu, and E. N. Fish
Protective Role for Interferon-{beta} in Coxsackievirus B3 Infection
Circulation, December 7, 2004; 110(23): 3540 - 3543.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Flodstrom, D. Tsai, C. Fine, A. Maday, and N. Sarvetnick
Diabetogenic Potential of Human Pathogens Uncovered in Experimentally Permissive {beta}-Cells
Diabetes, August 1, 2003; 52(8): 2025 - 2034.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. Kuhl, M. Pauschinger, P. L. Schwimmbeck, B. Seeberg, C. Lober, M. Noutsias, W. Poller, and H.-P. Schultheiss
Interferon-{beta} Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction
Circulation, June 10, 2003; 107(22): 2793 - 2798.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. M. Zhang, B. Yanagawa, P. Cheung, H. Luo, J. Yuan, D. Chau, A. Wang, L. Bohunek, J. E. Wilson, B. M. McManus, et al.
Nip21 Gene Expression Reduces Coxsackievirus B3 Replication by Promoting Apoptotic Cell Death via a Mitochondria-Dependent Pathway
Circ. Res., June 28, 2002; 90(12): 1251 - 1258.
[Abstract] [Full Text] [PDF]